Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy

被引:255
|
作者
Schrager, LK
D'Souza, MP
机构
[1] NIAID, Div Aids, Epidemiol Branch, Bethesda, MD 20892 USA
[2] NIAID, Div Aids, Pathogenesis & Basic Res Branch, Bethesda, MD 20892 USA
来源
关键词
D O I
10.1001/jama.280.1.67
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The eradication of human immunodeficiency virus 1 (HIV-1) from infected persons is the ultimate goal of HIV therapeutic interventions. Great strides have been made in developing potent antiretroviral regimens that greatly suppress HIV-1 replication. Despite these therapeutic advances, major obstacles remain to eradicating HIV-1. Reservoirs of HIV-1 have been identified that represent major impediments to eradication. Conceptually, there are 2 types of Sanctuaries for HIV-1, cellular and anatomical. Cellular sanctuaries may include latent CD4(+) T cells containing integrated HIV-1 provirus; macrophages, which may express HIV-1 for prolonged periods; and follicular dendritic cells, which may hold infectious HIV-1 on their surfaces for indeterminate lengths of time. The key anatomical reservoir for HIV-1 appears to be the central nervous system. An understanding of the nature of HIV within these reservoirs is critical to devising strategies to hasten viral eradication.
引用
收藏
页码:67 / 71
页数:5
相关论文
共 50 条
  • [41] Unmet therapeutic needs in the new era of combination antiretroviral therapy for HIV-1
    Taiwo, Babafemi
    Hicks, Charles
    Eron, Joseph
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2010, 65 (06) : 1100 - 1107
  • [42] Antiretroviral combination therapy in HIV-1 infected women and men: Are their responses different?
    Zorrilla, CD
    INTERNATIONAL JOURNAL OF FERTILITY AND WOMENS MEDICINE, 2000, 45 (02): : 195 - 199
  • [43] Neurologic Abnormalities in HIV-1 Infected Children in the Era of Combination Antiretroviral Therapy
    van Arnhem, Lotus A.
    Bunders, Madeleine J.
    Scherpbier, Henriette J.
    Majoie, Charles B. L. M.
    Reneman, Liesbeth
    Frinking, Olivier
    Poll-The, Bwee Tien
    Kuijpers, Taco W.
    Pajkrt, Dasja
    PLOS ONE, 2013, 8 (05):
  • [44] HIV-1 RNA is not detectable in the cerebrospinal fluid during antiretroviral combination therapy
    Gisslen, M
    Hagberg, L
    Svennerholm, B
    Norkrans, G
    AIDS, 1997, 11 (09) : 1194 - 1194
  • [45] The impact of HIV-1 infection, combination antiretroviral therapy and ageing on renal function
    Mandalia, S.
    Westrop, S. J.
    Beck, E. J.
    Nelson, M.
    Farrington, K.
    Imami, N.
    Gazzard, B.
    HIV MEDICINE, 2012, 13 : 48 - 49
  • [46] Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy
    Tebas, P
    Powderly, WG
    Claxton, S
    Marin, D
    Tantisiriwat, W
    Teitelbaum, SL
    Yarasheski, KE
    AIDS, 2000, 14 (04) : F63 - F67
  • [47] Quantification of HIV-1 p24 antigen to monitor patients during combination antiretroviral therapy
    Devereux, H
    Burke, A
    Campbell, K
    Dykoff, A
    Johnson, M
    Loveday, C
    AIDS, 1998, 12 : S74 - S74
  • [48] Frequency of HIV-1 Viral Load Monitoring of Patients Initially Successfully Treated with Combination Antiretroviral Therapy
    Romih, Vanja
    Lepej, Snjezana Zidovec
    Gedike, Kornelija
    Lukas, Davorka
    Begovac, Josip
    PLOS ONE, 2010, 5 (11):
  • [49] Outcome of HIV-1 infected patients with high viral load treated with combination antiretroviral therapy.
    Vande Waa, JA
    Vande Waa, EA
    Hoff, CJ
    Ramsey, KM
    JOURNAL OF INVESTIGATIVE MEDICINE, 1998, 46 (01) : 14A - 14A
  • [50] An immunological signature for subclinical atherosclerosis in people living with HIV-1 receiving antiretroviral therapy
    Salinas, T. R. Wiche
    Gosselin, A.
    Zhang, Y.
    Do Rosario, N. Fonseca
    Filali, A.
    Routy, J. -P.
    Chartrand-Lefebvre, C.
    Landay, A. L.
    Durand, M.
    El-Far, M.
    Tremblay, C.
    Ancuta, P.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 2 - 3